{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:07:14Z","timestamp":1792465634630,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["244-18-1067S"],"award-info":[{"award-number":["244-18-1067S"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005227","name":"Centers for Medicare & Medicaid Services","doi-asserted-by":"publisher","award":["244-18-1067S"],"award-info":[{"award-number":["244-18-1067S"]}],"id":[{"id":"10.13039\/100005227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Shingrix (recombinant zoster vaccine) was licensed to prevent herpes zoster, dispensed as 2 doses given 2\u20136 months apart among adults aged \u226550 years. Clinical trials yielded efficacy of &amp;gt;90% for confirmed herpes zoster, but post-market performance has not been evaluated. Efficacy of a single dose and a delayed second dose and efficacy among persons with autoimmune or immunosuppressive conditions have not been studied. We aimed to assess post-market vaccine effectiveness of Shingrix.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cohort study among Medicare Part D community-dwelling beneficiaries aged &amp;gt;65 years. Herpes zoster was identified using a medical office visit diagnosis with treatment, and postherpetic neuralgia was identified using a validated algorithm. We used inverse probability of treatment weighting to improve cohort balance and marginal structural models to estimate hazard ratios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found a vaccine effectiveness of 70.1% (95% confidence interval [CI], 68.6\u201371.5) and 56.9% (95% CI, 55.0\u201358.8) for 2 and 1 doses, respectively. The 2-dose vaccine effectiveness was not significantly lower for beneficiaries aged &amp;gt;80 years, for second doses received at \u2265180 days, or for individuals with autoimmune conditions. The vaccine was also effective among individuals with immunosuppressive conditions. Two-dose vaccine effectiveness against postherpetic neuralgia was 76.0% (95% CI, 68.4\u201381.8).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This large real-world observational study of the effectiveness of Shingrix demonstrates the benefit of completing the 2-dose regimen. Second doses administered beyond the recommended 6 months did not impair effectiveness. Our effectiveness estimates were lower than the clinical trials estimates, likely due to differences in outcome specificity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciab125","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T15:36:35Z","timestamp":1612971395000},"page":"941-948","source":"Crossref","is-referenced-by-count":138,"title":["Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure"],"prefix":"10.1093","volume":"73","author":[{"given":"Hector S","family":"Izurieta","sequence":"first","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Forshee","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Ming","family":"Sung","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Ehrlich","family":"Agger","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoganand","family":"Chillarige","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9617-806X","authenticated-orcid":false,"given":"Ruth","family":"Link-Gelles","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Lufkin","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wernecke","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E","family":"MaCurdy","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California, USA"},{"name":"Centers for Medicare & Medicaid Services, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kelman","sequence":"additional","affiliation":[{"name":"Centers for Medicare & Medicaid Services, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dooling","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"},{"name":"Department of Economics, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,13]]},"reference":[{"key":"2021091515513506200_CIT0001","author":"(FDA) FaDA"},{"key":"2021091515513506200_CIT0002","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Kathleen","year":"2018","journal-title":"Morb Mortal Wkly Rep"},{"key":"2021091515513506200_CIT0003","author":"(FDA) FaA"},{"key":"2021091515513506200_CIT0004","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/infdis\/jiw641","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US medicare beneficiaries in preventing postinfluenza deaths during 2012\u20132013 and 2013\u20132014","volume":"215","author":"Shay","year":"2017","journal-title":"J Infect Dis"},{"key":"2021091515513506200_CIT0005","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2021091515513506200_CIT0006","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2021091515513506200_CIT0007","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/j.vaccine.2011.04.019","article-title":"Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection","volume":"29","author":"Oxman","year":"2011","journal-title":"Vaccine"},{"key":"2021091515513506200_CIT0008","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"2021091515513506200_CIT0009","author":"(CMS) CfMaMS"},{"key":"2021091515513506200_CIT0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","article-title":"Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases","volume":"33","author":"Cooper","year":"2009","journal-title":"J Autoimmun"},{"key":"2021091515513506200_CIT0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1473-3099(14)71087-4","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using medicare data: a retrospective cohort analysis","volume":"15","author":"Izurieta","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021091515513506200_CIT0012","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4065\/mcp.2011.0305","article-title":"Herpes zoster and postherpetic neuralgia surveillance using structured electronic data","volume":"86","author":"Klompas","year":"2011","journal-title":"Mayo Clinic Proc"},{"key":"2021091515513506200_CIT0013","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1016\/j.vaccine.2019.07.004","article-title":"Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention","volume":"37","author":"Klein","year":"2019","journal-title":"Vaccine"},{"key":"2021091515513506200_CIT0014","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/pds.4801","article-title":"Zostavax vaccine effectiveness among US elderly using real-world evidence: Addressing unmeasured confounders by using multiple imputation after linking beneficiary surveys with medicare claims","volume":"28","author":"Izurieta","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021091515513506200_CIT0015","first-page":"8","article-title":"Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the medicare population ages 65 years and older","volume":"64","author":"Hector","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021091515513506200_CIT0016","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2021091515513506200_CIT0017","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/bmj.330.7497.960","article-title":"Reader\u2019s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding","volume":"330","author":"Mamdani","year":"2005","journal-title":"BMJ"},{"key":"2021091515513506200_CIT0018","volume-title":"Comparing mortality in renal patients on hemodialysis versus peritoneal dialysis using a marginal structural model","author":"van der Wal","year":"2011","edition":"1 ed"},{"key":"2021091515513506200_CIT0019","doi-asserted-by":"crossref","first-page":"Article 13","DOI":"10.2202\/1557-4679.1208","article-title":"Accuracy of conventional and marginal structural Cox model estimators: a simulation study","volume":"6","author":"Xiao","year":"2010","journal-title":"Int J Biostat"},{"key":"2021091515513506200_CIT0020","author":"AARP"},{"key":"2021091515513506200_CIT0021","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"2021091515513506200_CIT0022","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021091515513506200_CIT0023","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5021\/ad.2018.30.2.253","article-title":"Validation of herpes zoster diagnosis code in the electronic medical record: a retrospective, multicenter study","volume":"30","author":"Kim","year":"2018","journal-title":"Ann Dermatol"},{"key":"2021091515513506200_CIT0024","author":"GSK"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab125\/39804728\/ciab125.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/6\/941\/40392324\/ciab125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/6\/941\/40392324\/ciab125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T08:03:17Z","timestamp":1671177797000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/6\/941\/6134290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,13]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,2,13]]},"published-print":{"date-parts":[[2021,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab125","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,15]]},"published":{"date-parts":[[2021,2,13]]}}}